Search the Newsreel

Prime Medicine (NASDAQ:PRME) Trading Up 7.3% - Still a Buy?

Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME

Renaissance Technologies LLC has reduced its stake in Prime Medicine, Inc. (NASDAQ:PRME) by 35.5%, selling 408,120 shares but still retaining 741,039 shares valued at approximately $2.58 million. This comes as Prime Medicine reported a quarterly loss of $0.24 per share, meeting analyst estimates, yet …

Prime Medicine (NASDAQ:PRME) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Prime Medicine (NASDAQ:PRME) from a "strong sell" to a "sell" rating, while other analysts maintain a "Moderate Buy" consensus with an average price target of $7.53. The company's shares opened at $3.08, significantly below its 52-week high, and it met …

Prime Medicine, Inc. 2026: Revenue $11.04M, EPS ($0.24) — 10-Q Summary

Prime Medicine, Inc. (PRME) reported its Q2 2026 financial results, showing revenue of $11.04 million and a net loss of ($42.11M), resulting in a diluted EPS of ($0.24). This represents a decrease in revenue but an improvement in net loss and EPS compared to …

BRIEF-Prime Medicine, Inc. Q2 EPS USD -0.24

Prime Medicine, Inc. reported its Q2 earnings per share (EPS) at USD -0.24. This brief update was sourced from Reuters and made available on TradingView.

Prime Medicine expects 2027 data from two liver gene therapies

Prime Medicine reported its second-quarter 2026 financial results, including a narrowed net loss of $42.1 million and cash reserves of $108.8 million, expected to fund operations into 2027. The company announced significant pipeline progress, with initial clinical data for its two liver gene therapies, …

Prime Medicine (NASDAQ:PRME) Announces Earnings Results, Meets Estimates

Prime Medicine (NASDAQ:PRME) announced its earnings results, reporting a quarterly loss of $0.24 per share, which matched analysts' consensus estimates. Despite this, the company continues to face deeply negative profitability metrics, including a net margin of -4,917.55%. Shares traded down to $2.95, near its …

Prime Medicine, Inc. (PRME) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Prime Medicine, Inc. (PRME), including its current stock price, trading activity, historical data, and company overview. It highlights key financial metrics, recent news, performance comparisons against the S&P 500, and analyst ratings, alongside details of its …

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) reported a Q2 loss of $0.24 per share, aligning with Zacks Consensus Estimate but missing revenue estimates significantly at $1.15 million. The company has consistently missed revenue expectations over the last four quarters, and its shares have underperformed the S&P …

FDA milestones and Beam ruling frame outlook for Prime Medicine (NASDAQ: PRME)

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

Prime Medicine has reported its second-quarter 2026 financial results, highlighting significant progress in its clinical programs. The company received IND and CTA clearances for PM577a in Wilson disease, securing a global Phase 1/2 program, and an arbitration resolution affirmed its rights to PM647 for …

Prime Medicine (PRME) Earnings Date and Reports 2026

PRME|Prime Medicine Inc|Price:2.935|Chg%:+0.125

This article provides a comprehensive stock analysis of Prime Medicine Inc (PRME) from TradingKey, highlighting its "fairly valued" status within the Biotechnology & Medical Research industry. The company, which specializes in gene editing therapies, has significant growth potential, high institutional ownership, and a strong …

Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages

Prime Medicine, Inc. (NASDAQ:PRME) has received an average "Moderate Buy" recommendation from eight brokerages, with six analysts rating it a buy, one a strong buy, and one a sell. The average 12-month price target is $7.53, significantly higher than its recent share price of …

Prime Medicine(PRME) Stock Options Chain | Quotes & News

This article provides access to the stock options chain for Prime Medicine (PRME), including detailed quotes and relevant news. It serves as a resource for investors interested in the company's options trading data and market developments.

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Prime Medicine, Inc. (PRME) is expected to report a year-over-year increase in earnings and higher revenues for Q2 2026. However, Zacks' Earnings ESP model, which compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggests that analysts have recently become bearish, resulting in …

Redmile Group LLC Takes $5.54 Million Position in Prime Medicine, Inc. $PRME

Redmile Group LLC has acquired a new position in Prime Medicine, Inc. (NASDAQ:PRME) worth approximately $5.54 million, making it their 28th largest holding. Other institutional investors have also adjusted their stakes in the gene editing company. Analysts currently have an average "Moderate Buy" rating …

ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME

ADAR1 Capital Management LLC has initiated a new position in Prime Medicine, Inc. (NASDAQ:PRME) by purchasing 1,973,282 shares valued at approximately $6.87 million during the first quarter. This investment makes ADAR1 Capital Management LLC the owner of about 1.09% of Prime Medicine. Several other …

Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Prime Medicine Inc (PRME), noting that relevant data for business segments and profit contribution have not yet been disclosed by the company for FY2025 and FY2024. It highlights that the company reported $4.63 million in revenue from …

Prime Medicine Market Sentiment

This article provides an overview of market sentiment for Prime Medicine (PRME), detailing analyst consensus, short interest, options flow, and recent analyst actions. Key signals show a "Buy" analyst consensus, 24.6% short float, and a 1.58 P/C ratio for options. The article also lists …

Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME

This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically focusing on its forward price-to-earnings ratio. The content appears to be a financial data page from TradingView, indicating the company's stock market status and offering various analytical tools and data points.

Oppenheimer Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $11

Oppenheimer has reiterated its Buy rating for Prime Medicine (PRME.US), maintaining a target price of $11. This indicates continued confidence in the company's prospects from the investment firm.

Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History

This article provides a detailed financial overview of Prime Medicine, Inc. (PRME), including its current stock price, recent performance, key financial metrics, and company overview. It highlights the company's biotechnology focus on genetic medicines and its lead therapeutic product candidates, along with analyst insights …

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine has received U.S. FDA clearance for its Investigational New Drug (IND) application for PM577a, an in vivo Prime Editor for Wilson disease (WD). This clearance, combined with a previously approved New Zealand Clinical Trial Application, establishes a global Phase 1/2 clinical program. …

Prime Medicine expects first-in-human Wilson trial in second half of 2026

Prime Medicine (Nasdaq: PRME) announced that the U.S. FDA cleared its Investigational New Drug (IND) application for PM577a, an investigational in vivo Prime Editor for Wilson disease. This clearance, combined with a previously approved Clinical Trial Application in New Zealand, allows for a global …

Prime Medicine receives FDA clearance for Wilson disease therapy By Investing.com

Prime Medicine Inc. announced that the FDA has cleared its Investigational New Drug application for PM577a, a gene editing treatment for Wilson disease. This clearance, combined with a previous approval in New Zealand, allows the company to proceed with a global Phase 1/2 clinical …

Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify

Cathie Wood's ARK Invest made significant portfolio adjustments on Monday, focusing on increasing holdings in gene editing, AI infrastructure, and space economy companies like Prime Medicine, Tempus AI, and SpaceX. Simultaneously, ARK reduced positions in certain biotech firms such as AtaiBeckley, e-commerce platform Shopify, …